| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |